MARKHAM, ON, Nov. 25 /CNW/ - Cytochroma today announced the appointment of Peter Moldt, PhD to its Board of Directors. Dr. Moldt will replace Mr. Ulrik Spork as the Novo A/S representative on the Company's Board. The number of Board members remains unchanged at six members.
"We are very pleased to welcome Peter Moldt to the board and look forward to benefiting from his experience and guidance as Cytochroma continues to make progress in becoming a leading CKD-focused specialty pharmaceutical company," stated Alan Lewis, PhD, Chairman of Cytochroma's Board of Directors. "We are grateful for the advice that Ulrik Spork has provided to Cytochroma over the past year, and wish him well in the future."
Dr. Moldt has significant experience in corporate strategy, company operations, and drug development. He was most recently CEO of Curalogic A/S, a company he cofounded in 2004 and subsequently took public. Before Curalogic A/S, he was Chief Operating Officer of 7TM Pharma A/S, a company which he cofounded in 2000. Prior to 2000, Dr. Moldt spent 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. Dr. Moldt holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy, and has been a post-doc with Yale University's Department of Organic Chemistry.
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD. CTA018 Injection is being developed in partnership with Mitsubishi Tanabe Pharma Corporation for the U.S. and Asian markets, and Cytochroma retains co-promotion rights for this product in the U.S. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.
For more information about Cytochroma, please visit www.cytochroma.com.
For further information: For further information: Cytochroma Investors: Gordon Ngan, Executive Director, Corporate Development, Tel: (905) 479-5306 ext. 333, email@example.com; Cytochroma Media: Robert Stanislaro (FD), Tel: (212) 850-5657, firstname.lastname@example.org